Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mirati Therapeutics (NQ: MRTX )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mirati Therapeutics

< Previous 1 2 3 4 5 6 7 8 Next >
Mirati Posts Adagrasib Data In KRAS-Mutated Lung Cancer, FDA Filing Now On The Cards
After data readout from KRAS drug adagrasib in colon cancer, Mirati Therapeutics Inc (NASDAQ: MRTX) has announced positive topline results from a Phase... 
Via Benzinga
Exposures Product Safety
Mirati Showcases New KRAS Drug Data In Colorectal Cancer At ESMO
Mirati Therapeutics Inc (NASDAQ: MRTX) announced results from the 600mg BID dose cohort of the Phase 1/2 KRYSTAL–1 study evaluating adagrasib in heavily... 
Via Benzinga
The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight
Biotech stocks declined for the week ending Sept. 17, extending the losses from the previous week. European Society for Medical Oncology presentations, vaccine news, clinical... 
Via Benzinga
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For August 26, 2021
Upgrades Scotiabank upgraded the previous rating for Enerplus Corp (NYSE: 
Via Benzinga
Mirati's KRAS Inhibitor Receives FDA Breakthrough Tag For Lung Cancer Harboring KRAS Mutation
The FDA has granted Breakthrough Therapy designation to Mirati Therapeutics Inc's (NASDAQ: MRTX) adagrasib in non-small cell lung cancer (NSCLC) patients... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24) AngioDynamics, Inc. (NASDAQ... 
Via Benzinga
Exposures COVID-19
20 Stocks Moving in Friday's Pre-Market Session
Gainers Fuwei Films (Holdings) Co., Ltd. (NASDAQ: FFHL) rose 83.4% to $16.34 in pre-market trading after the company reported a sharp rise in Q1 earnings and sales. Grove, Inc. (... 
Via Benzinga
A Peek Into The Markets: US Stock Futures Up Following Thursday's Rally; Nike Posts Upbeat Results
Pre-open movers U.S. stock futures traded higher in early pre-market trade. The Dow Jones surged more than 300 points, while the S&P 500 closed at a record high in the... 
Via Benzinga
Topics Stocks
Exposures US Equities
7 Stocks Moving In Thursday's After-Hours Session
Gainers Mirati Therapeutics (NASDAQ: MRTX) shares are trading higher after the company announced it received Breakthrough Therapy Designation from the FDA for patients with... 
Via Benzinga
Exposures Product Safety
14 Biotech Stocks To Watch Over The Next 6 Months
Biotechs are at the mercy of several make-or-break catalysts that invariably have a big impact on stocks. A case in point was the strong upside in Biogen Inc.'s (NASDAQ:... 
Via Benzinga
Week In Review: Zai Lab Enters $338 Million Agreement To In-License KRAS Inhibitor
Shanghai's Zai Lab in-licensed Greater China rights to adagrasib, a KRASG12C inhibitor, from Mirati of San Diego in a $338 million agreement. Mirati will receive a $65 million upfront payment and up to... 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For June 4, 2021
Upgrades According to Argus Research, the prior rating for Diageo PLC (NYSE:DEO) was changed from Hold to Buy. The current stock performance of Diageo shows a 52-week-high... 
Via Benzinga
The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 25) ESSA Pharma Inc. (NASDAQ:... 
Via Benzinga
QIAGEN Partners With Mirati Therapeutics Inc. to Develop KRASG12C Companion Diagnostic for Non-Small Cell Lung Cancer (NSCLC)
From QIAGEN N.V.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 17, 2021
Upgrades B of A Securities upgraded the previous rating for Kosmos Energy Ltd (NYSE:KOS) from Neutral to Buy. In the first quarter, Kosmos Energy showed an EPS of $0.08,... 
Via Benzinga
10 Biggest Price Target Changes For Monday
Morgan Stanley boosted the price target on Applied Materials, Inc. (NASDAQ: AMAT) from $113 to $137. Applied Materials shares fell 1.1% to $123.46 in pre-market trading.... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2021
Upgrades Barrington Research upgraded the previous rating for ViacomCBS Inc (NASDAQ:VIAC) from Market Perform to Outperform. For the first quarter, ViacomCBS had an EPS of... 
Via Benzinga
10 Biggest Price Target Changes For Monday
BMO Capital boosted The Middleby Corporation (NASDAQ: MIDD) price target from $225 to $250. Middleby shares rose 1.9% to close at $182.83 on Friday. Atlantic Equities reduced... 
Via Benzinga
The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight
Contrary to the strength in the broader market, biotech stocks ended the week ending April 9 lower. The weakness partly reflected a preference for risky bets at the expense of... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.